News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
IOMAI Corporation Likely to Sell to Intercell AG Sooner than Expected
July 14, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Iomai Corp. has received federal regulatory approval to sell itself to an Austrian life sciences company, helping speed up the sale's timetable by a month.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Rare diseases
Novo Offers up to $2.1B for Omeros’ Complement Drug To Expand Rare Disease Work
October 15, 2025
·
2 min read
·
Dan Samorodnitsky
ALS
BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line
October 15, 2025
·
1 min read
·
Tristan Manalac
Mergers & acquisitions
BioCryst Snaps Up Fellow Angiodema Player Astria for $700M
October 15, 2025
·
2 min read
·
Tristan Manalac
Podcast
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
October 15, 2025
·
1 min read
·
Heather McKenzie
